Actinogen Medical Limited

4:00 PM - 4:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 103
Actinogen is an ASX-listed, biotech company conducting Ph 2 trials of an oral, brain-penetrant small molecule for Alzheimer’s Disease (AD) and cognitive impairment associated with Depression. Xanamem® works by a novel, non-amyloid mechanism to reduce tissue cortisol by inhibition of the intracellular enzyme, 11β-HSD1. Cortisol is strongly associated with detrimental brain changes affecting cognition.

Xanamem safety has been demonstrated in >300 people treated to date. Improved attention & working memory were seen in 2 randomized trials & clinically significant improvements in function & cognition in mild AD patients were observed in a 3rd randomized trial.

A Ph 2b trial in 330 patients with early-stage AD will commence soon & a Ph 2a trial in 160 patients with depression & cognitive impairment initiated in Dec 2022.

Actinogen is proactively engaging with prospective global and regional biopharma partners that wish to collaborate on development and commercialization of Xanamem.
Australian Stock Exchange
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Chief Executive Officer
Actinogen Medical Limited